Mark R. BamforthFounder, President & CEO, Brammer Bio
In 2015 Mark founded Brammer Biopharmaceuticals, a cell and gene therapy CMO, subsequently merged in March 2016 with Florida Biologix to create Brammer Bio. Previously, Mark founded Gallus BioPharmaceuticals, a premier CDMO delivering clinical and commercial mammalian based biopharmaceuticals which was sold to DPx Holdings B.V. (Patheon) in September 2014. Mark spent 22 years in the UK and USA, running global operations and a pharmaceutical CMO business for Genzyme Corp. His work at Genzyme included supporting cell therapy and gene therapy clinical trials resulting in the first FDA approval of a cell therapy product. Mark began his career as a petroleum engineer, exploring for North Sea oil, then as a chemical engineer in the whisky industry. He serves on the MassBio Board and is a founding trustee of the Saltire Foundation. He has a BS in Chemical Engineering from Strathclyde University and an MBA from Henley Management College.